CAR T Therapy Shows Early Promise in Stiff Person Syndrome - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CAR T Therapy Shows Early Promise in Stiff Person Syndrome

  • November 18, 2026

  • 3 min

Share

Objective:

To evaluate the efficacy and safety of mivocabtagene autoleucel in adults with antibody-positive stiff person syndrome (SPS) who had responded inadequately to prior immunomodulatory treatment.

Approach:
  • Design: Multicenter, open-label phase 2 KYSA-8 trial enrolling 27 adults; 26 received one infusion after low-dose lymphodepleting chemotherapy.
  • Assessment: The primary efficacy endpoint was change in the timed 25-foot walk test at week 16. Secondary outcomes included stiffness, hypersensitivity, disability, and mobility; safety and biomarkers were also assessed.
Key Findings:
  • At week 16, the median improvement in timed 25-foot walk performance was 45.6%; more than 80% of participants had clinically meaningful improvement in walking speed.
  • Eight of 12 participants who initially used walking aids no longer required them.
  • Improvements were reported across secondary measures. All 26 treated participants remained off SPS-directed immunomodulatory or immunosuppressive therapy at latest follow-up, which had a median duration of 6.5 months.
  • Peripheral B-cell depletion was observed by day five. Among participants with elevated GAD65 autoantibodies, median antibody levels fell 56% by week 16.
  • Cytokine release syndrome occurred in 92.3% of participants, all at grade 1 or 2; three had grade 1 neurotoxicity, and five (19.2%) had grade 3 or 4 neutropenia. No deaths or adverse-event-related discontinuations were reported.
Interpretation:

The trial authors reported improvements in mobility and other SPS measures after a single infusion. They stated that long-term follow-up to establish the durability of benefits is in progress.

Limitations:
  • The trial was open-label and included 26 treated participants.
  • Latest follow-up had a median duration of 6.5 months; durability of benefit remains under investigation.
Sources:

Original Source(s)

Related Content